IDL Biotech is making progress in Africa | IDL Biotech
IDL Biotech

CLOSE MENU

Articles

Typhiod fever

April 2021

IDL Biotech is making progress in Africa

IDL Biotech has now received its first order from the company's distributor in Uganda, Medilink Lab & Surgical Ltd. The order refers to TUBEX® TF, IDL Biotech's rapid test for typhoid fever. Uganda will thus be the third country in Africa to which the company delivers TUBEX® TF.

It is a small initial order, but crucial as it also means a start to a planned local evaluation study. The study is managed and controlled by the distributor and the local authorities and is considered to be very important for the continued marketing in Uganda, and also in other neighboring countries. In many cases today, a fast and effective diagnostic method for typhoid fever is lacking. TUBEX® TF can therefore make a big difference and contribute to more patients receiving the right treatment in time.

“It is very positive that the use of TUBEX® TF can now start in Africa. We have already signed distributor agreements in a number of countries, but covid-19 has unfortunately led to delays in planned activities. ” says Gunnar Wahlberg, CEO of IDL Biotech. 

Read the full press release here (Swedish)

IDL Biotech signs distributor agreement in Ghana

IDL Biotech continues to expand in Africa. IDL Biotech has signed a distributor agreement with Res Health Consult Ltd covering Ghana. The agreement covers the sale of TUBEX® TF.

IDL Biotech includes additional clinics in its ongoing multicenter study for UBC® Rapid in Sweden.

IDL Biotech currently has a number of ongoing clinical studies both internationally and in Sweden, with the aim of demonstrating the clinical benefit of UBC® Rapid in bladder cancer and having the test included as a complement in the follow-up of patients with bladder cancer who are classified as high risk.

IDL Biotech

Skip this intro